Literature DB >> 26535489

N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42.

Olga Szczepankiewicz1, Björn Linse1, Georg Meisl2, Eva Thulin1, Birgitta Frohm1, Carlo Sala Frigerio3, Michael T Colvin4, Angela C Jacavone4, Robert G Griffin4, Tuomas Knowles2, Dominic M Walsh3,5, Sara Linse1.   

Abstract

Amyloid β-protein (Aβ) sequence length variants with varying aggregation propensity coexist in vivo, where coaggregation and cross-catalysis phenomena may affect the aggregation process. Until recently, naturally occurring amyloid β-protein (Aβ) variants were believed to begin at or after the canonical β-secretase cleavage site within the amyloid β-protein precursor. However, N-terminally extended forms of Aβ (NTE-Aβ) were recently discovered and may contribute to Alzheimer's disease. Here, we have used thioflavin T fluorescence to study the aggregation kinetics of Aβ42 variants with N-terminal extensions of 5-40 residues, and transmission electron microscopy to analyze the end states. We find that all variants form amyloid fibrils of similar morphology as Aβ42, but the half-time of aggregation (t1/2) increases exponentially with extension length. Monte Carlo simulations of model peptides suggest that the retardation is due to an underlying general physicochemical effect involving reduced frequency of productive molecular encounters. Indeed, global kinetic analyses reveal that NTE-Aβ42s form fibrils via the same mechanism as Aβ42, but all microscopic rate constants (primary and secondary nucleation, elongation) are reduced for the N-terminally extended variants. Still, Aβ42 and NTE-Aβ42 coaggregate to form mixed fibrils and fibrils of either Aβ42 or NTE-Aβ42 catalyze aggregation of all monomers. NTE-Aβ42 monomers display reduced aggregation rate with all kinds of seeds implying that extended termini interfere with the ability of monomers to nucleate or elongate. Cross-seeding or coaggregation may therefore represent an important contribution in the in vivo formation of assemblies believed to be important in disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26535489      PMCID: PMC5412961          DOI: 10.1021/jacs.5b07849

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  58 in total

1.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

Review 2.  The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

Authors:  John Hardy
Journal:  J Neurochem       Date:  2009-05-18       Impact factor: 5.372

3.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

Authors:  C J Pike; M J Overman; C W Cotman
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

Review 4.  Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide.

Authors:  C Haass; D J Selkoe
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

5.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

6.  Supramolecular structure in full-length Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance.

Authors:  John J Balbach; Aneta T Petkova; Nathan A Oyler; Oleg N Antzutkin; David J Gordon; Stephen C Meredith; Robert Tycko
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

7.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides.

Authors:  Georg Meisl; Xiaoting Yang; Erik Hellstrand; Birgitta Frohm; Julius B Kirkegaard; Samuel I A Cohen; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-17       Impact factor: 11.205

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

10.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.

Authors:  Samuel I A Cohen; Sara Linse; Leila M Luheshi; Erik Hellstrand; Duncan A White; Luke Rajah; Daniel E Otzen; Michele Vendruscolo; Christopher M Dobson; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

View more
  23 in total

1.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

2.  Aggregation and Fibril Structure of AβM01-42 and Aβ1-42.

Authors:  Robert Silvers; Michael T Colvin; Kendra K Frederick; Angela C Jacavone; Susan Lindquist; Sara Linse; Robert G Griffin
Journal:  Biochemistry       Date:  2017-08-30       Impact factor: 3.162

3.  Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis.

Authors:  Angie C A Chiang; Stephanie W Fowler; Rohit Reddy; Olga Pletnikova; Juan C Troncoso; Mathew A Sherman; Sylvain E Lesne; Joanna L Jankowsky
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

Review 4.  Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Paolo Arosio
Journal:  Pharm Res       Date:  2017-09-28       Impact factor: 4.200

5.  Imaging Aβ(1-42) fibril elongation reveals strongly polarised growth and growth incompetent states.

Authors:  Laurence J Young; Gabriele S Kaminski Schierle; Clemens F Kaminski
Journal:  Phys Chem Chem Phys       Date:  2017-10-25       Impact factor: 3.945

6.  Expression of N-Terminal Cysteine Aβ42 and Conjugation to Generate Fluorescent and Biotinylated Aβ42.

Authors:  Sheng Zhang; Gretchen Guaglianone; Michael A Morris; Stan Yoo; William J Howitz; Li Xing; Jian-Guo Zheng; Hannah Jusuf; Grace Huizar; Jonathan Lin; Adam G Kreutzer; James S Nowick
Journal:  Biochemistry       Date:  2021-04-01       Impact factor: 3.321

7.  A Robust and Efficient Production and Purification Procedure of Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides.

Authors:  Marie Hoarau; Yannick Malbert; Romain Irague; Christelle Hureau; Peter Faller; Emmanuel Gras; Isabelle André; Magali Remaud-Siméon
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

Review 8.  Monomer-dependent secondary nucleation in amyloid formation.

Authors:  Sara Linse
Journal:  Biophys Rev       Date:  2017-08-15

Review 9.  AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species.

Authors:  Francesco Simone Ruggeri; Johnny Habchi; Andrea Cerreta; Giovanni Dietler
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Stereochemistry and amyloid inhibition: Asymmetric triplex metallohelices enantioselectively bind to Aβ peptide.

Authors:  Yijia Guan; Zhi Du; Nan Gao; Yue Cao; Xiaohui Wang; Peter Scott; Hualong Song; Jinsong Ren; Xiaogang Qu
Journal:  Sci Adv       Date:  2018-01-19       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.